Cereno Scientific reports one new patient enrolled, one additional patient randomized, and one additional patient completed in the Phase II Study of CS1 in PAH
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that one new additional patient have been enrolled in the study, one additional patient has been randomized on CS1 drug and one additional patient has completed the study. This update serves as the latest progress update for the Phase II study of drug candidate CS1 in rare disease pulmonary arterial hypertension (PAH). The study is set to be completed by Q3 2024.The Phase II study of CS1 in the rare disease PAH is actively running at 10